Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Immuno-Oncology Therapeutics: Pharmacological Profiles and Clinical Challenges
*Corresponding Author: Oluwaseun Chung, Directorate of Postgraduate Studies, School of Medicine, Muhimbili University of Health and Allied Sciences, Tanzania, Email: oluwaseun99chungg@gmail.comReceived Date: Jul 01, 2024 / Published Date: Jul 30, 2024
Citation: Oluwaseun C (2024) Immuno-Oncology Therapeutics: PharmacologicalProfiles and Clinical Challenges. Clin Pharmacol Biopharm, 13: 472.
Copyright: © 2024 Oluwaseun C. This is an open-access article distributed underthe terms of the Creative Commons Attribution License, which permits unrestricteduse, distribution, and reproduction in any medium, provided the original author andsource are credited.
Abstract
Immuno-oncology (IO) has transformed cancer treatment by leveraging the body's immune system to combat tumors. This article explores the pharmacological profiles and clinical challenges of IO therapeutics, focusing on checkpoint inhibitors, CAR-T cell therapy, cytokine therapy, and oncolytic viruses. While these therapies have shown remarkable efficacy, challenges such as biomarker identification, immune-related adverse events, resistance mechanisms, and accessibility remain. Future directions include enhancing specificity of checkpoint inhibitors, exploring neoantigen vaccines, and understanding the role of microbiome modulation. Addressing these challenges is crucial for advancing IO therapies and improving outcomes for cancer patients
